Trupanion, Inc. (NASDAQ:TRUP) Receives $41.83 Consensus PT from Analysts

Shares of Trupanion, Inc. (NASDAQ:TRUP) have received a consensus recommendation of “Moderate Buy” from the seven ratings firms that are currently covering the firm, MarketBeat reports. Three investment analysts have rated the stock with a hold recommendation, three have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $41.83.

A number of research analysts have recently commented on TRUP shares. Northland Securities upped their price objective on shares of Trupanion from $35.00 to $45.00 and gave the company a “market perform” rating in a research note on Thursday, September 19th. William Blair started coverage on shares of Trupanion in a report on Friday, July 19th. They issued an “outperform” rating on the stock. Piper Sandler boosted their price objective on shares of Trupanion from $38.00 to $45.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 2nd. Stifel Nicolaus raised their target price on shares of Trupanion from $30.00 to $40.00 and gave the company a “hold” rating in a research note on Monday, September 23rd. Finally, Bank of America upped their price target on shares of Trupanion from $47.00 to $56.00 and gave the stock a “buy” rating in a research report on Friday, September 20th.

Trupanion Stock Up 1.0 %

Shares of Trupanion stock opened at $53.61 on Friday. The stock has a market capitalization of $2.25 billion, a PE ratio of -83.77 and a beta of 1.73. Trupanion has a 52-week low of $19.14 and a 52-week high of $55.74. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.63 and a current ratio of 1.63. The company has a 50-day simple moving average of $46.12 and a two-hundred day simple moving average of $35.24.

Trupanion (NASDAQ:TRUP) last announced its quarterly earnings results on Thursday, August 8th. The financial services provider reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.04. Trupanion had a negative return on equity of 6.29% and a negative net margin of 1.57%. The firm had revenue of $314.80 million for the quarter, compared to the consensus estimate of $309.33 million. During the same period in the prior year, the company posted ($0.33) earnings per share. The company’s quarterly revenue was up 16.3% on a year-over-year basis. On average, analysts anticipate that Trupanion will post -0.34 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Margaret Tooth sold 7,500 shares of the business’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $46.48, for a total value of $348,600.00. Following the transaction, the chief executive officer now owns 99,984 shares in the company, valued at approximately $4,647,256.32. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Trupanion news, CEO Margaret Tooth sold 7,500 shares of the firm’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $46.48, for a total transaction of $348,600.00. Following the completion of the transaction, the chief executive officer now directly owns 99,984 shares of the company’s stock, valued at $4,647,256.32. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Fawwad Qureshi sold 640 shares of the stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $43.12, for a total transaction of $27,596.80. The disclosure for this sale can be found here. Insiders have sold 8,764 shares of company stock valued at $405,238 in the last quarter. Company insiders own 5.50% of the company’s stock.

Institutional Investors Weigh In On Trupanion

Institutional investors have recently made changes to their positions in the company. GAMMA Investing LLC lifted its holdings in shares of Trupanion by 70.4% in the 3rd quarter. GAMMA Investing LLC now owns 1,442 shares of the financial services provider’s stock worth $61,000 after purchasing an additional 596 shares during the last quarter. Headlands Technologies LLC bought a new stake in Trupanion during the second quarter worth approximately $162,000. Handelsbanken Fonder AB acquired a new stake in shares of Trupanion in the third quarter valued at $248,000. Oppenheimer Asset Management Inc. acquired a new stake in Trupanion in the 2nd quarter valued at about $235,000. Finally, Bayesian Capital Management LP bought a new stake in Trupanion during the first quarter worth approximately $253,000.

Trupanion Company Profile

Trupanion, Inc, together with its subsidiaries, provides medical insurance for cats and dogs on a monthly subscription basis in the United States, Canada, Continental Europe, and Australia. The company operates in two segments, Subscription Business and Other Business. It serves pet owners and veterinarians.